. TNF--stimulated VCAM-1 expression in lung tissue is dependent on FAK activity. (A) Experimental timeline. Oral administration of FAK-I (100 mg/kg, PND-1186) was administrated 3 h before TNF- tail vein injection (0.02 mg/kg), and tissues were collected at 6 h for immunoblotting after TNF- stimulation. (B) Lung lysates were analyzed for VCAM-1, pY397 FAK, and total FAK blotting. Actin was used as loading controls (Con). (C) Lung-associated VCAM-1 expression or FAK activation (pY397) was measured by densitometry, and ratios to actin and total FAK were determined. Values are means (±SD; **, P < 0.001; ****, P < 0.0001) from six mice, representing two independent experiments. Figure S2 . Visualization of TNF--stimulated FAK activation and VCAM-1 expression within heart ECs. In vivo signaling assays were performed with C57BL6 mice pretreated with vehicle or FAK-I (100 mg/kg, PND-1186) by tail vein injection of recombinant TNF- (0.02 mg/kg) or PBS. Hearts were isolated after 6 h, and frozen sections were analyzed by combined indirect immunofluorescent staining. (A) Staining for ECs (CD31) and activated FAK (pY576). In the merged images, yellow staining indicates sites of pY576 FAK and CD31 costaining. (B) Staining for ECs (CD31) and VCAM-1. In the merged images, yellow staining indicates sites of VCAM-1 and CD31 costaining. Bars, 20 µm. Figure S3 . Gene ontology and signaling network analyses of mRNA array data from FAK-WT and FAK-KD embryos. (A) Shown is Ingenuity Pathway Analysis (Ingenuity Systems) evaluation of Illumina mRNA array data identifying biological processes differentially regulated by FAK activity. The threshold was set at a threefold change, and the y axis is the p-value (log scale). Functional annotation groups (x axis) with genes within the leukocyte extravasation signaling shown as the most significant difference between FAK-WT and FAK-KD embryos. (B) Network analyses map within the leukocyte extravasation signaling group. mRNA target changes are represented as nodes, with known direct (solid lines) and indirect (dashed lines) interactions indicated. The asterisks show genes that were identified multiple times in different pathway analyses (shown in A). LDL, low-density lipoprotein; HGF, hepatocyte growth factor; TCR, T cell receptor; WAS, Wiskott-Aldrich syndrome. Figure S4 . FAK activity is not required for TNF--stimulated NF-B activation. (A) NF-B EMSA was performed with nuclear extracts isolated from FAK-WT and FAK-KD MEF TNF- stimulation (10 ng/ml, 30 min), as indicated. The arrow indicates activated NF-B, and 100-fold unlabeled NF-B probes were added as a cold competitor. (B) NF-B EMSA was performed with HUVEC extracts upon TNF- stimulation (10 ng/ml, 30 min), as indicated. FAK-I pretreatment (1 µM PF271, 1 h) did not block stimulated NF-B DNA binding upon TNF- treatment. Excess unbound 2 P-labeled probes are present in each lane. Figure S5 . FAK inhibition blocks TNF-a-induced ERK/MAPK but not NF-B activation in lung lysates. (A) Experimental timeline. FAK-I (100 mg/kg, PND-1186) was given 3 h before TNF- (0.02 mg/kg) or PBS tail vein injection, and lung tissues were collected after 5 min for immunoblotting or after 3 h for evaluation of NF-B activation. (B) Lung lysates analyzed for FAK Y397 phosphorylation, total FAK, activated ERK (pERK; pT202/pY204), total ERK, and actin. Con, control. (C) Nuclear lysates were isolated from lung tissues, and NF-B EMSA was performed. Pharmacological FAK inhibition (100 mg/kg, PND-1186) did not change in vivo NF-B activity upon TNF- signaling.
